|
Age (per year)
|
1.11 (1.04–1.18)
|
0.001
|
|
Sex (male)
|
0.65 (0.28–1.51)
|
0.320
|
|
ACS at presentation (presence)
|
0.99 (0.41–2.41)
|
0.983
|
|
CV risk profile
|
|
BMI (per kg/m2)
|
0.91 (0.82–1.00)
|
0.059
|
|
Waist circumference (per 10 cm)
|
0.94 (0.68–1.30)
|
0.718
|
|
Hypertension (presence)
|
0.94 (0.28–3.17)
|
0.923
|
|
Hyperlipidemia (presence)
|
0.70 (0.30–1.66)
|
0.704
|
|
Total cholesterol (per 10 mg/dl)
|
1.05 (0.95–1.16)
|
0.313
|
|
LDL-c (per 10 mg/dl)
|
1.07 (0.94–1.21)
|
0.311
|
|
HDL-c (per 10 mg/dl)
|
1.43 (1.02–1.99)
|
0.036
|
|
Triglycerides (per 10 mg/dl)
|
0.98 (0.92–1.04)
|
0.447
|
|
Active smoking (presence)
|
0.99 (0.37–2.66)
|
0.981
|
|
Pack years (per 10 py)
|
0.95 (0.79–1.16)
|
0.637
|
|
Family history of CAD (presence)
|
0.35 (0.14–0.89)
|
0.351
|
|
Previous CAD (presence)
|
1.99 (0.88–4.52)
|
0.099
|
|
Previous PCI (presence)
|
1.93 (0.85–4.41)
|
0.118
|
|
Previous CABG (presence)
|
2.29 (0.31–17.1)
|
0.418
|
|
hsCRP (per 10 mg/dl)
|
1.06 (0.93–1.22)
|
0.375
|
|
GFR (per 10 mg/dl/1.73 m2)
|
0.49 (0.27–0.90)
|
0.020
|
|
Other comorbidities
|
|
COPD (presence)
|
1.30 (0.44–3.48)
|
0.638
|
|
Diabetes severity and therapy
|
|
Diabetes duration (per year)
|
1.03 (0.99–1.06)
|
0.125
|
|
Diabetic polyneuropathy (presence)
|
2.94 (1.29–6.68)
|
0.010
|
|
Diabetic retinopathy (presence)
|
1.90 (0.75–4.82)
|
0.178
|
|
HbA1c (per 1%)
|
1.34 (0.92–1.97)
|
0.131
|
|
Insulin (presence)
|
3.44 (1.45–8.13)
|
0.005
|
|
Metformin (presence)
|
0.40 (0.17–0.90)
|
0.028
|
|
Sulfonylamides (presence)
|
0.73 (0.25–2.16)
|
0.575
|
|
Incretins (presence)
|
2.11 (0.87–5.14)
|
0.100
|
|
Other relevant medication
|
|
Aspirin (presence)
|
1.21 (0.16–8.96)
|
0.854
|
|
Statin (presence)
|
0.54 (0.24–1.24)
|
0.149
|
|
ACE or ARBi (presence)
|
0.76 (0.31–1.85)
|
0.547
|
|
Beta-blocker (presence)
|
0.52 (0.22–1.24)
|
0.142
|
